Pharmaceutical company Dr. Reddy's Laboratories Ltd (NSE:DRREDDY) (NYSE:RDY) reported on Friday the availability of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) in the US market.
The company revealed Carmustine for Injection, USP is a therapeutic equivalent generic version of BiCNU (carmustine for injection), which is approved by the US Food and Drug Administration (USFDA).
In addition, Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 ml sterile diluent, stated the company.
According to IQVIA Health, the BiCNU brand and generic market had U.S. sales of approximately USD19.4m MAT for the most recent 12 months ending in August 2021. iCNU is a trademark owned or licensed by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Carmustine is used to treat cancer of lymphatic system, brain and certain types of cancers of bone marrow. It may be used to treat other types of cancer. It can be used alone, or together with certain other medicines as part of combination chemotherapy, added the company.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling